Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL)
Melani, C. J., Lakhotia, R., Pittaluga, S., Phelan, J. D., Yang, Y., Davies‐Hill, T., Simard, J., Muppidi, J., Huang, D. W., Thomas, C. J., Ceribelli, M., Tosto, F. A., Pradhan, A., Juanitez, A. M., Rimsza, L. M., Jacob, A., Simmons, H., Steinberg, S. M., Jaffe, E. S., Staudt, L. M., Roschewski, M., Wilson, W. H.
Published in Hematological oncology (01.06.2023)
Published in Hematological oncology (01.06.2023)
Get full text
Journal Article
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023
Melani, C J, Lakhotia, R, Pittaluga, S, Phelan, J D, Yang, Y, Davies-Hill, T, Simard, J, Muppidi, J, Huang, D W, Thomas, C J, Ceribelli, M, Tosto, F A, Pradhan, A, Juanitez, A M, Rimsza, L M, Jacob, A, Simmons, H, Steinberg, S M, Jaffe, E S, Staudt, L M, Roschewski, M, Wilson, W H
Published in Hematological oncology (01.06.2023)
Published in Hematological oncology (01.06.2023)
Get full text
Journal Article
PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B‐CELL LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS
Melani, C.J., Lakhotia, R., Pittaluga, S., Miljkovic, M.D., Portell, C.A., Farah, R.J., Juanitez, A.M., Chou, L.L., Steinberg, S.M., Jaffe, E.S., Staudt, L.M., Roschewski, M.J., Wilson, W.H.
Published in Hematological oncology (01.06.2019)
Published in Hematological oncology (01.06.2019)
Get full text
Journal Article